医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

C.C.Medico Announces the Launch of Wrapping Foundation AirSkin®, the Cosmetic That Exquisitely Wraps You Like a Lovely Gift

2014年12月23日 AM02:30
このエントリーをはてなブックマークに追加


 

TOKYO

C.C.Medico.Co., Ltd. has developed AirSkin®, a wrapping foundation that exquisitely wraps your skin like a lovely gift with an attractive wrapping film. AirSkin® is not spread on like previous cosmetic products. It is a completely new type of cover-up foundation that uses a microns-thick skin-colored film that users apply to their skin.

YouTube “This is AirSkin ® (60 seconds)”

Although we at C.C.Medico have been involved in developing cover-up cosmetic products to hide blemishes, bruises, dullness, and surgical and natural scars, we were never able to develop a product that could completely cover these skin conditions using liquid or powder based cosmetics.

We discovered from a member of our testing group , that they would conceal tattoos using tape. This led us to move from developing spread-on foundation to engage in the development of an applied foundation.

Since this newly perfected AirSkin® is based on a method that transfers a microns-thick skin-colored film onto the user’s skin, it has several advantages over previous foundations. These include the ability to cover uniformly without blotches as well as greatly improved water resistance, scratch resistance, and durability.

Starting this Christmas, we will deliver AirSkin® – the product that will exquisitely wrap you like a dazzling gift – to the world.

WEB SHOP SANNA’S (Payment accepted in USD, EUR, BRL, and JPY)

In English

In Portuguese

In Spanish

[Company Overview]

Website

AirSkin Website

CONTACT

C.C.Medico Co.,Ltd.
Mayu Ishikawa, +81-3-5942-5536
ccmedico@me.com
fax:
+81-3-5542-5529

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024